N-acetyl cysteine therapy in acute viral hepatitis

World Journal of Gastroenterology

Volumn 9, Issue 12, 2003, Pages 2698-2700

  Gunduz, Huseyin ^a   Karabay, Oguz ^a   Tamer, Ali ^a   Özaras, Resat ^b   Tabak, Ömer Fehmi ^b  

^a ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLOBULIN; PLACEBO; PROTHROMBIN;

ACUTE DISEASE; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; FOLLOW UP; HEPATITIS A; HEPATITIS B; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; JAUNDICE; LENGTH OF STAY; LIVER FUNCTION TEST; MALE; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; VIRUS HEPATITIS;

EID: 0347598079     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i12.2698     Document Type: Article

References (27)

1. Banker DD. Viral hepatitis. Indian J Med Sci 2003; 57: 363-368
2. Mathur P, Arora NK. Considerations for HAV vaccine in India. Indian J Pediatr 2001; 68(Suppl 1): 23-30
3. Batra Y, Bhatkal B, Ojha B, Kaur K, Saraya A, Panda SK, Acharya SK. Vaccination against hepatitis A virus may not be required for schoolchildren in northern India: Results of a seroepidemiological survey. Bull World Health Organ 2002; 80: 728-731
4. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23: 437-455
5. Ertekin V, Selimoglu MA, Altinkaynak S. Sero-epidemiology of hepatitis B infection in an urban paediatric population in Turkey. Public Health 2003; 117: 49-53
6. Khan WI, Sultana R, Rahman M, Akhter H, Haq JA, Ali L, Mohsin MA, Khan AK. Viral hepatitis: Recent experiences from serological studies in Bangladesh. Asian Pac J Allergy Immunol 2000; 18: 99-103
7. Centers for Disease Control and Prevention (CDC). Transmission of hepatitis B and C viruses in outpatient settings - New York, Oklahoma, and Nebraska, 2000-2002. MMWR Morb Mortal Wkly Rep 2003; 52: 901-906
8. Gregory PB, Knauer CM, Kempson RL, Miller R. Steroid therapy in severe viral hepatitis, a double blind, randomized trial of methylprednisolone versus placebo. N Eng J Med 1976; 294: 681-687
9. Mackenzie AR, Molyneaux PJ, Cadwgan AM, Laing RB, Douglas JG, Smith CC. Increasing incidence of acute hepatitis B virus infection referrals to the Aberdeen Infection Unit: A matter for concern. Scott Med J 2003; 48: 73-75
10. Kucukardali Y, Cinan U, Acar HV, Ozkan S, Top C, Nalbant S, Cermik H, Cankir Z, Danaci M. Comparison of the therapeutic efficacy of 4-methylpyrazole and N-acetylcysteine on acetaminophen (paracetamol) hepatotoxicity in rats. Curr Med Res Opin 2002; 18: 78-81
11. Zhao C, Sheryl D, Zhou YX. Effects of combined use of diallyl disulfide and Nacetyl-cysteine on acetaminophen hepatotoxicity in β-naphthoflavone-pretreated mice. World J Gastroenterol 1998; 4: 112-116
12. Flanagan RJ, Meredith TJ. Use of N-acetylcysteine in clinical toxicology. Am J Med 1991; 91(Suppl 3C): 131-139
13. Neri S, Ierna D, Antoci S, Campanile E, D'Amico RA, Noto R. Association of alpha-interferon and acetyl cysteine in patients with chronic C hepatitis. Panminerva Med 2000; 423: 187-192
14. Beloqui O, Prieto J, Suarez M, Gil B, Qian CH, Garcia N, Civeira MP. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: A pilot study. J Interferon Res 1993; 13: 279-282
15. Grand PR, Black A, Garcia N, Prieto J, Garson JA. Combination therapy with interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: A placebo controlled double-blind multicentre study. J Med Virol 2000; 61: 439-442
16. Weiss L, Hildt E, Hofschneider PH. Anti hepatitis B virus activity of N acetylcysteine, new aspect a well established drug. Antiviral Res 1996; 32: 43-53
17. Mandal AK, Sinha J, Mandal S, Mukhopadhyay S, Das N. Targeting of liposomal flavonoid to liver in combating hepatocellular oxidative damage. Drug Deliv 2002; 9: 181-185
18. Wie J, Wang YQ, Lu ZM, Li GD, Wang Y, Zhang ZC. Detection of anti-preS1 antibodies for recovery of hepatitis B patients by immunoassay. World J Gastroenterol 2002; 8: 276-281
19. T.C Government Statically Instuty. Stastical Annual of Turkey Republic 1993: 151-154
20. Ozturk R. Laboratory diagnosis of viral hepatitis. Yucel A, Tabak F (Eds): Currently Viral Hepatitis. Istanbul Infectious Diseases Association's publications 1998; 11: 53-54
21. Ozdemir O, Arda K, Soylu M, Alyan O, Demi AD, Kutuk E. Seroprevalence of hepatitis B and C in subjects admitted to a cardiology clinics in Turkey. Eur J Epidemiol 2003; 18: 255-258
22. Shiell A, Law MG. The cost of hepatitis C and the cost-effectiveness of its prevention. Health Policy 2001; 58: 121-131
23. Jacobs RJ, Saab S, Meyerhoff AS, Koff RS. An economic assessment of pre-vaccination screening for hepatitis A and B. Public Health Rep 2003; 118: 550-558
24. Maier I, Wu GY. Hepatitis C and HIV co-infection: A review. World J Gastroenterol 2002; 8: 577-579
25. Ryder SD, Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system: Acute hepatitis. BMJ 2001; 322: 151-153
26. MacNee W, Bridgeman MME, Marsden M. Effects of N-acetylcysteine and glutathione on smoke induced changes in lung phagocytes and epithelial cells. Am J Med 1991; 91(Suppl 3C): 60-71
27. Taylor ER, Hurrell F, Shannon RJ, Lin TK, Hirst J, Murphy MP. Reversible glutathionylation of complex I increases mitochondrial superoxide formation. J Biol Chem 2003; 278: 19603-19610